Listed

Amphastar Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2016

Filed with the SEC on Mar 15, 2017 and accepted by EDGAR at Mar 14, 2017, 18:57 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-10-01 to 2016-12-31$63.5mus-gaap:SalesRevenueNet
Cost of revenue12 months2016-01-01 to 2016-12-31$151.0mus-gaap:CostOfRevenue
Gross profit3 months2016-10-01 to 2016-12-31$20.0mus-gaap:GrossProfit
Gross profit12 months2016-01-01 to 2016-12-31$104.2mus-gaap:GrossProfit
Research and development12 months2016-01-01 to 2016-12-31$41.2mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2016-01-01 to 2016-12-31$15.7mus-gaap:OperatingIncomeLoss
Interest expense12 months2016-01-01 to 2016-12-31$1.0mus-gaap:InterestExpense
Income tax12 months2016-01-01 to 2016-12-31$4.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-10-01 to 2016-12-31−$2.7mus-gaap:NetIncomeLoss
Net income12 months2016-01-01 to 2016-12-31$10.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-10-01 to 2016-12-31−$0.06us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2016-01-01 to 2016-12-31$0.22us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-10-01 to 2016-12-31−$0.06us-gaap:EarningsPerShareBasic
Basic EPS12 months2016-01-01 to 2016-12-31$0.23us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-10-01 to 2016-12-3146,104,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)12 months2016-01-01 to 2016-12-3147,504,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Capital expenditure12 months2016-01-01 to 2016-12-31$21.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2016-01-01 to 2016-12-31$9.9mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2016-12-31$72.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-12-31$184.1mus-gaap:AssetsCurrent
Total assetsAt period end2016-12-31$427.7mus-gaap:Assets
Current liabilitiesAt period end2016-12-31$60.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-12-31$98.5mus-gaap:Liabilities
Long-term debtAt period end2016-12-31$36.0mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2016-12-31$329.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001297184-17-000007. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.